FibroBiologics to Host In-Person Analyst Day to Provide Research & Development Updates
FibroBiologics (Nasdaq: FBLG), a clinical-stage biotechnology company focusing on fibroblast-based therapeutics for chronic diseases, has announced two significant upcoming events. The company will host an in-person analyst day on February 12, 2025, at 2:00 p.m. ET at the New York Marriott Marquis.
The analyst day will feature presentations from key management members, including CEO Pete O'Heeron, CSO Hamid Khoja, PhD, and Interim CFO Robert Hoffman. The event will showcase the company's research and development strategy for fibroblast-based therapeutics, followed by a live Q&A session.
Additionally, FibroBiologics will present at the 2025 BIO CEO & Investor Conference in New York on February 11 at 11:15 a.m. ET. The presentation will take place in the Plymouth Room at the New York Marriott Marquis.
FibroBiologics (Nasdaq: FBLG), un'azienda biotecnologica in fase clinica che si concentra sulle terapie a base di fibroblasti per malattie croniche, ha annunciato due eventi significativi in arrivo. L'azienda ospiterà un giorno di analisi in presenza il 12 febbraio 2025, alle 14:00 ET, presso il New York Marriott Marquis.
Il giorno di analisi includerà presentazioni dei membri chiave della direzione, tra cui il CEO Pete O'Heeron, il CSO Hamid Khoja, PhD, e il CFO ad interim Robert Hoffman. L'evento presenterà la strategia di ricerca e sviluppo dell'azienda per le terapie a base di fibroblasti, seguito da una sessione di domande e risposte dal vivo.
Inoltre, FibroBiologics presenterà al 2025 BIO CEO & Investor Conference a New York l'11 febbraio alle 11:15 ET. La presentazione si terrà nella Plymouth Room presso il New York Marriott Marquis.
FibroBiologics (Nasdaq: FBLG), una empresa de biotecnología en etapa clínica que se centra en terapias basadas en fibroblastos para enfermedades crónicas, ha anunciado dos eventos importantes que se avecinan. La empresa organizará un día de análisis en persona el 12 de febrero de 2025, a las 2:00 p.m. ET en el New York Marriott Marquis.
El día de análisis contará con presentaciones de miembros clave de la gerencia, incluyendo al CEO Pete O'Heeron, al CSO Hamid Khoja, PhD, y al CFO interino Robert Hoffman. El evento mostrará la estrategia de investigación y desarrollo de la empresa para las terapias basadas en fibroblastos, seguido de una sesión de preguntas y respuestas en vivo.
Además, FibroBiologics presentará en la 2025 BIO CEO & Investor Conference en Nueva York el 11 de febrero a las 11:15 a.m. ET. La presentación se llevará a cabo en la Plymouth Room del New York Marriott Marquis.
FibroBiologics (Nasdaq: FBLG)는 만성 질환에 대한 섬유아세포 기반 치료법에 집중하는 임상 단계의 생명공학 회사로, 다가오는 두 가지 중요한 이벤트를 발표했습니다. 이 회사는 2025년 2월 12일 오후 2시 ET에 뉴욕 메리어트 마퀴스에서 대면 애널리스트 데이를 개최합니다.
애널리스트 데이에서는 CEO Pete O'Heeron, CSO Hamid Khoja 박사, 그리고 임시 CFO Robert Hoffman을 포함한 주요 경영진의 발표가 있을 예정입니다. 이 이벤트는 섬유아세포 기반 치료법에 대한 회사의 연구 및 개발 전략을 선보이며, 이후 실시간 Q&A 세션이 진행됩니다.
추가로, FibroBiologics는 2025년 2월 11일 오전 11:15 ET에 뉴욕에서 열리는 2025 BIO CEO & Investor Conference에 발표할 예정입니다. 발표는 뉴욕 메리어트 마퀴스의 플리머스 룸에서 진행됩니다.
FibroBiologics (Nasdaq: FBLG), une entreprise de biotechnologie en phase clinique axée sur les thérapies à base de fibroblastes pour les maladies chroniques, a annoncé deux événements significatifs à venir. L'entreprise organisera un jour d'analyste en personne le 12 février 2025 à 14h00 ET au New York Marriott Marquis.
Le jour d'analyste présentera des interventions de membres clés de la direction, notamment le PDG Pete O'Heeron, le CSO Hamid Khoja, PhD, et le CFO interim Robert Hoffman. L'événement mettra en lumière la stratégie de recherche et développement de l'entreprise pour les thérapies à base de fibroblastes, suivi d'une session de questions-réponses en direct.
De plus, FibroBiologics présentera à la 2025 BIO CEO & Investor Conference à New York le 11 février à 11h15 ET. La présentation se tiendra dans la Plymouth Room du New York Marriott Marquis.
FibroBiologics (Nasdaq: FBLG), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf fibroblast-basierte Therapeutika für chronische Krankheiten konzentriert, hat zwei bedeutende bevorstehende Veranstaltungen angekündigt. Das Unternehmen wird am 12. Februar 2025 um 14:00 Uhr ET einen persönlichen Analystentag im New York Marriott Marquis ausrichten.
Der Analystentag wird Präsentationen von wichtigen Führungskräften beinhalten, darunter CEO Pete O'Heeron, CSO Hamid Khoja, PhD, und Interim CFO Robert Hoffman. Die Veranstaltung wird die Forschungs- und Entwicklungsstrategie des Unternehmens für fibroblast-basierte Therapeutika vorstellen, gefolgt von einer Live-Q&A-Session.
Zusätzlich wird FibroBiologics am 11. Februar um 11:15 Uhr ET auf der 2025 BIO CEO & Investor Conference in New York präsentieren. Die Präsentation findet im Plymouth Room im New York Marriott Marquis statt.
- None.
- None.
FibroBiologics to also present at the BIO CEO & Investor Conference
HOUSTON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced that it will host an in-person analyst day at the New York Marriott Marquis on February 12, 2025, at 2:00 p.m. ET.
The event will feature presentations from the following members of the Company's management:
- Pete O’Heeron, Chief Executive Officer
- Hamid Khoja, PhD, Chief Scientific Officer
- Robert Hoffman, Interim Chief Financial Officer
The event will highlight FibroBiologics’ research and development strategy for advancing fibroblast-based therapeutics to address chronic diseases.
A live Q&A session will follow the formal presentations. An audio recording of the presentation and Q&A will be available under the investor section of the FibroBiologics website after the event.
In addition, FibroBiologics will be presenting at the 2025 BIO CEO & Investor Conference in New York, NY, from February 10-11. Details of the event are as follows:
Date: Tuesday, February 11
Time: 11:15 a.m. ET
Location: The New York Marriott Marquis
Track: Plymouth Room
To learn more about the event, please visit https://bcic.bio.org/, or to schedule one-on-one meetings, please email FibroBiologicsIR@russopr.com.
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 160+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, visit www.FibroBiologics.com.
General Inquiries:
info@fibrobiologics.com
Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com
FAQ
When and where is FibroBiologics (FBLG) hosting its analyst day in 2025?
What will be discussed at FibroBiologics' (FBLG) February 2025 analyst day?
When is FibroBiologics (FBLG) presenting at the 2025 BIO CEO & Investor Conference?
How many patents does FibroBiologics (FBLG) currently have issued and pending?
Which executives will be presenting at FibroBiologics' (FBLG) February 2025 analyst day?
